Supplementary Figure 1.

Comparison	AUC	Significant clones (p<0.05)		
		C1q	LDL (1)	IL-8-(1)
SLE vs. Normal	0.63	↓	↑	
SLE (3-14*) vs. Normal	0.57	↓	↑	
SLE (16-32)* vs. Normal	0.76	↓	↑	
SLE (3-10)* vs. Normal	0.43		↑	
SLE (12-17)* vs. Normal	0.57			
SLE (18-32)* vs. Normal	0.87	↓		↓

*= SLEDAI-2K

Supplementary Figure 1

Protein expression profiling of biotinylated serum using the miniaturized 48-plex antibody array platform and normalized with the subtract by geometric group mean strategy. The SLE nephritis patients was grouped based on SLEDAI-2K, first into two broad groups based on high (16-32) and low (3-14) disease activity and second into three groups low (3-10), mid (12-17) and high (18-32) disease activity. The classification of SLE nephritis patients and healthy controls was performed using a leave one out cross validation test, illustrated as AUC values. Differentially expressed (p<0.05) serum analytes, identified using Wilcoxon signed ranked test.